Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer.
Fiche publication
Date publication
janvier 2016
Journal
Future oncology (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle, Pr FALCOZ Pierre-Emmanuel, Dr GUENOT Dominique, Dr GUERIN Eric, Dr MENNECIER Bertrand, Pr MEYER Nicolas, Pr NOEL Georges
Tous les auteurs :
Renaud S, Schaeffer M, Voegeli AC, Legrain M, Guérin E, Meyer N, Mennecier B, Quoix E, Falcoz PE, Guénot D, Massard G, Noël G, Beau-Faller M
Lien Pubmed
Résumé
Our study aimed to evaluate response rate (RR) to brain metastasis radiotherapy (RT), depending on the genomic status of non-small-cell lung cancer.
Mots clés
Adult, Aged, Aged, 80 and over, Amino Acid Substitution, genetics, Brain Neoplasms, genetics, Carcinoma, Non-Small-Cell Lung, genetics, Disease-Free Survival, Female, Genetic Association Studies, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Mutation, Polymorphism, Single Nucleotide, Proto-Oncogene Proteins p21(ras), genetics, Radiation Tolerance, genetics, Receptor, Epidermal Growth Factor, genetics
Référence
Future Oncol. 2016 Jan;12(1):59-70